Lay Description

The goal of this study is to learn if circulating tumor DNA and other tumor-related molecules/chemicals released in the blood can help doctors predict if colorectal cancer may come back or spread.


  • Cancers and Other Neoplasms
  • Colorectal Cancer
IRB Number
NCT Number registration not required
Open to Enrollment


Eligible Ages
18 and above
Eligible Genders
Accepts Healthy Volunteers

Inclusion Criteria

1.            Age ≥ 18 years.

2.            Histological/cytological confirmation of colorectal adenocarcinoma.

3.            Patients with any stage colorectal adenocarcinoma deemed potentially eligible for curative intent treatment.  Patients with stages II-IV colorectal cancer post-R0 resection may also be enrolled onto the protocol any time before or up to 3 months post-surgery and prior to initiating adjuvant therapy.

4.            Ability to understand and the willingness to sign a written informed consent document.

5.            Willing to pursue standard of care surveillance post completion of curative therapies.

6.            Willing to provide blood samples for correlative research.

Exclusion Criteria

1.            Known active malignancies other than colorectal adenocarcinoma that may interfere with detection and / or interpretation of circulating plasma markers. Patients with known clonal hematopoiesis of indeterminate potential are eligible.

2.            Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study.

Study Design

Arm Groups

Study Contact

Frances Crawford
(210) 450-5037

Sonia Creighton
(210) 450-1366

Myrna Montenegro
(210) 450-5954

Courtney Nichols
(210) 450-1794

Mailbox Ctrc Regulatory Affairs

Kathleen Rodriguez
(210) 450-1365

Benjamin Schleif
(210) 450-1366

Morgan Seekatz
(210) 450-1133

Principal Investigator
Colin Court